[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. He J, Wang DZ, Zheng GY, Feng G: [Detection of P-glycoprotein and glutathine S-transferase in mucoepidermoid carcinoma of salivary gland]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2004 Apr;22(2):115-6, 151
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of P-glycoprotein and glutathine S-transferase in mucoepidermoid carcinoma of salivary gland].
  • OBJECTIVE: The aim of this study was to investigate the mechanism(MDR) of multidrug resistance(MDR) of mucoepidermoid carcinoma in salivary gland.
  • METHODS: 40 cases of mucoepidermoid carcinoma in salivary gland were examined the MDR gene product P-glycoprotein using a monoclonal antibody JSB-1.
  • All the cases had not been accepted any therapy before the samples were collected.
  • CONCLUSION: JSB-1 and GST-pi play an important role in MDR of mucoepidermoid carcinoma.
  • [MeSH-major] Carcinoma, Mucoepidermoid / immunology. Glutathione Transferase / analysis. Isoenzymes / analysis. P-Glycoprotein / analysis. Salivary Gland Neoplasms / immunology. Salivary Glands / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / analysis. Child. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Genes, MDR. Glutathione S-Transferase pi. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15190791.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Isoenzymes; 0 / P-Glycoprotein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


2. Dahse R, Kosmehl H: Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer; 2008 Jul 8;99(1):90-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
  • By screening salivary gland carcinoma, two drug-sensitizing EGFR exon 19 delE746-A750 mutations were identified in an adenocystic and in a mucoepidermoid carcinoma of the parotid gland.
  • [MeSH-major] Drug Resistance / genetics. Parotid Neoplasms / drug therapy. Parotid Neoplasms / genetics. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Aged. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / genetics. DNA, Neoplasm / genetics. Erlotinib Hydrochloride. Exons. Female. Humans. Male. Middle Aged. Mutation. Quinazolines / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] Pathol Int. 2007 May;57(5):233-44 [17493170.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • (PMID = 18542074.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC2453031
  •  go-up   go-down


5. Pacheco-Ojeda L, Domeisen H, Narvaez M, Tixi R, Vivar N: Malignant salivary gland tumors in Quito, Ecuador. ORL J Otorhinolaryngol Relat Spec; 2000 Nov-Dec;62(6):296-302
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant salivary gland tumors in Quito, Ecuador.
  • OBJECTIVES: Malignant salivary gland tumors (MSGT) are uncommon.
  • The goal of this study was to review a 16-year experience of a major general hospital in the treatment of these lesions.
  • PATIENTS AND METHODS: From 1982 to 1998, 308 salivary gland tumors were surgically treated at the Hospital 'Carlos Andrade Marin' of the Ecuadorian Institute of Social Security in Quito, Ecuador, an Andean city of approximately 2 million inhabitants.
  • Malignant lesions were found in 58 cases (19%): 37 out of 194 parotid gland tumors (19%), 7 out of 86 submandibular tumors (8%) and 14 out of 28 minor salivary gland tumors (50%).
  • Adenoid cystic carcinoma and mucoepidermoid carcinoma were the most common histologic types.
  • Thirty-one (53%) patients were treated by surgery alone; postoperative radiation therapy was additionally given to 22 (38%), and surgery, radiotherapy and chemotherapy were applied in 5 cases (9%).
  • Twelve patients (21%) developed distant metastasis (DM; 2 in more than one site): 7 in the lungs, 2 in the brain, 2 in the bone and 1 each in the liver, subcutaneous tissue and pleura.
  • There were no significant differences in mortality according to the site of the primary tumor or histologic type, but stage and involved surgical margins were important prognostic factors (p = 0.006 and 0.003).
  • CONCLUSIONS: The surgical or multimodality treatment of MSGT has provided a good locoregional control (78%) and 68% 10-year survival in a series of patients treated at the oncology department of a general hospital in Quito, Ecuador.
  • [MeSH-major] Carcinoma, Adenoid Cystic / therapy. Carcinoma, Mucoepidermoid / therapy. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Ecuador / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Salivary Glands / pathology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 11054011.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 31
  •  go-up   go-down


6. Woo HJ, Bai CH, Kim YD, Song SY: Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child. Auris Nasus Larynx; 2009 Apr;36(2):244-6
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
  • Although there are many reports describing SMN in patients treated for childhood cancer, salivary gland tumors rarely appear in these reports.
  • Radiotherapy is a well-known risk factor for the development of secondary salivary gland malignancies after the treatment of childhood cancer.
  • However, it is not well known whether chemotherapy itself treatment increases the risk of salivary gland malignancies.
  • We report a child case with mucoepidermoid carcinoma of the submandibular gland as a SMN after chemotherapy alone for acute myeloid leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Mucoepidermoid / chemically induced. Leukemia, Myeloid, Acute / drug therapy. Neoplasms, Second Primary / chemically induced. Submandibular Gland Neoplasms / chemically induced
  • [MeSH-minor] Adolescent. Biopsy. Busulfan / adverse effects. Busulfan / therapeutic use. Child. Child, Preschool. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Cytarabine / adverse effects. Cytarabine / therapeutic use. Daunorubicin / adverse effects. Daunorubicin / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Disease-Free Survival. Etoposide / adverse effects. Etoposide / therapeutic use. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Image Processing, Computer-Assisted. Male. Neck Dissection. Positron-Emission Tomography. Thioguanine / adverse effects. Thioguanine / therapeutic use. Tomography, X-Ray Computed. Transplantation Conditioning

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602781.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; FTK8U1GZNX / Thioguanine; G1LN9045DK / Busulfan; ZS7284E0ZP / Daunorubicin; DCTER protocol
  •  go-up   go-down


7. Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, Madami L: Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):182-90
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major salivary gland diseases. Multicentre study.
  • Malignant tumours instead were fewer in number compared to the literature (14% vs 25-30%); the most frequent being mucoepidermoid carcinoma (18.2%) of which 44% G1, 33% G2 and 23% G3.
  • Adenoid-cystic carcinoma was observed in 15.3% and < or = 10% for all the other most frequent histological malignant neoplasms.
  • Diagnostic work-up included echotomography and fine-needle aspiration biopsy, less used imaging techniques were computed tomography, magnetic resonance imaging, Sialo-computed tomography.
  • Surgical treatment of benign tumours consisted, in 50% of cases, in superficial paroditectomy and in approximately 30% of total paroditectomy.
  • The lateral neck dissection most frequently carried out was of functional type in 54% and selective type in 46% with removal of levels I-III and II-IV in approximately 60% of cases.
  • Post-operative-complementary radiotherapy was very frequently performed instead of chemotherapy.
  • Oncological results obtained were compared with those reported in the literature: in fact for all benign neoplasms relapse ratings are about 5%, while for malignant tumours the worst prognosis was in squamous cell carcinoma with median of 37.7 on survival and metastasis rate of 16.5%.
  • Finally, mucoepidermoid carcinoma tumours showed best survival, followed by adenoid-cystic carcinoma with ranges, respectively, 83 and 81.
  • [MeSH-major] Salivary Gland Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1984-8 [11801983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):729-38 [11849796.001]
  • [Cites] Atlas Oral Maxillofac Surg Clin North Am. 1998 Mar;6(1):1-28 [11905347.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):285-7 [11945190.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Apr;22(2):80-5 [12068476.001]
  • [Cites] J Laryngol Otol. 2002 May;116(5):359-62 [12080993.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Mund Kiefer Gesichtschir. 2003 Mar;7(2):94-101 [12664254.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):257-9 [12903612.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):624-9 [12956917.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):929-33 [12975263.001]
  • [Cites] World J Surg. 2003 Jul;27(7):863-7 [14509520.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Chir Ital. 2003 Nov-Dec;55(6):857-64 [14725226.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Otolaryngol Pol. 2004;58(1):109-14 [15101269.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):113-27 [15062365.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Feb;23(1):53-6 [15804023.001]
  • [ErratumIn] Acta Otorhinolaryngol Ital. 2005 Oct;25(5):following 337
  • (PMID = 16450775.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639866
  •  go-up   go-down


8. Lennerz JK, Perry A, Mills JC, Huettner PC, Pfeifer JD: Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion. Am J Surg Pathol; 2009 Jun;33(6):835-43
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion.
  • Mucoepidermoid carcinoma (MEC) of the uterine cervix is a controversial entity.
  • By strict morphologic criteria, the tumor has features identical to those of salivary gland MEC and is characterized by nests composed of 3 cell types (epidermoid, intermediate, and mucin producing) in the absence of overt glandular differentiation.
  • Given the morphologic similarity between MEC of the cervix and MEC of the salivary glands, we sought to determine if MEC of the cervix harbors the t(11;19)(q21;p13) characteristic of MEC of the major and minor salivary glands, a rearrangement that results in fusion of the cyclic adenosine 3',5' monophosphate coactivator CRTC1 to the Notch coactivator MAML2.
  • Our results demonstrate that cervical tumors defined as MEC by strict morphologic criteria harbor genetic aberrations involving the genes characteristically rearranged in MEC of the salivary glands, and suggest that cervical MEC is an entity distinct from conventional cervical adenosquamous carcinoma.
  • The development of drug therapy targeted to the genes rearranged in MEC underscores the importance of correct classification of cervical MEC because the diagnosis may hold therapeutic implications different from other cervical malignancies.

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092631.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062; United States / NIDDK NIH HHS / DK / R01 DK079798; United States / NIDDK NIH HHS / DK / R01 DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062-05; United States / NIDDK NIH HHS / DK / DK066062-05
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


9. Hicks J, Flaitz C: Mucoepidermoid carcinoma of salivary glands in children and adolescents: assessment of proliferation markers. Oral Oncol; 2000 Sep;36(5):454-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of salivary glands in children and adolescents: assessment of proliferation markers.
  • Malignant neoplasms represent one-third of all pediatric salivary gland tumors.
  • Mucoepidermoid carcinoma (MEC) composes 51% of malignant tumors and 16% of all salivary gland neoplasms in pediatrics.
  • Histopathologic features, clinical outcomes and proliferation markers in 26 pediatric patients (median age 11 years; 19F:7M) with salivary gland MECs were evaluated retrospectively.
  • Treatment was surgical in 21 cases, and surgery with chemotherapy and radiotherapy in five cases.
  • MECs were second malignancies in two children with prior radiotherapy and chemotherapy for leukemia and histiocytosis.
  • Low and intermediate grade salivary gland MECS in a pediatric population may have a favorable outcome when compared with high grade MECs.
  • Proliferation markers appear to be linked to histocytologic MEC grade and may provide information regarding biologic behavior of salivary gland MECs in children and adolescents.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Mucoepidermoid / chemistry. Salivary Gland Neoplasms / chemistry

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10964053.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


10. Sakamoto K, Izumaru S, Kurita T, Miyajima Y, Nakashima T: [Clinical review of mucoepidermoid carcinomas]. Nihon Jibiinkoka Gakkai Kaiho; 2005 Feb;108(2):142-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical review of mucoepidermoid carcinomas].
  • Mucoepidermoid carcinoma is a rare head and neck cancer tumor, composed of both mucous and epidermoid cells.
  • We retrospectively reviewed the case of 36 such patients hospitalized in the last 24 years (between 1978 and 2002) at Kurume University Hospital, focusing on origin, treatment, and treatment outcome.
  • In this study, 33 patients undergoing currative treatment were studied in detail.
  • Tumors originated in major salivary glands in 24 and in the oral cavity, paranasal cavity, and oropharynx in 3 each.
  • Salivary gland carcinomas were graded, clinically and histopathologically based on the criteria of Goode et al. as follows: low (n = 3), intermediate (n = 3), and high (n = 18).
  • Five-year overall survival was 64%, i.e., 56% in salivary gland malignancy, 67% in oral cavity malignancy, 100% in paranasal cavity malignancy and 100% in oropharynx malignancy.
  • In 31 patients not undergoing chemotherapy, 6 died of distant metastasis.
  • These results emphasize the necessity of radiotherapy and chemotherapy after surgical treatment for head and neck mucoepidermoid carcinoma.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765727.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Airoldi M, Fornari G, Pedani F, Marchionatti S, Gabriele P, Succo G, Bumma C: Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res; 2000 Sep-Oct;20(5C):3781-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and carboplatin for recurrent salivary gland malignancies.
  • BACKGROUND: The use of chemotherapy for recurrent salivary gland carcinomas is under investigation.
  • PATIENTS AND METHODS: Fourteen patients (10 males, 4 females; median age 55 years, range 20-70) with recurrent carcinomas of major (9 patients) and minor (5 patients) salivary gland origin (histology: 1 adenocarcinoma, 10 adenoid cystic carcinoma, 2 undifferentiated carcinoma, 1 mucoepidermoid carcinoma) were treated with carboplatin AUC 5.5 + paclitaxel 175 mg/m2 (3-hour infusion) on day 1 (interval = 3 weeks).
  • The median survival time was 13.5 months for PR/NC patients, 6 months for non responders; median overall survival was 12.5 months (3-17+).
  • CONCLUSION: This combination had a moderate activity; the treatment was well tolerated and toxicity was manageable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Paclitaxel / administration & dosage. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268454.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland tumors in survivors of childhood cancer.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • Although, ionizing radiation has been demonstrated to increase the risk of developing a salivary gland neoplasm, there are few reports of salivary gland neoplasms occurring in patients treated for cancer in childhood.
  • RESULTS: Twelve survivors of childhood cancer developed a salivary gland neoplasm after completion of treatment.
  • These patients were initially treated for a variety of childhood cancers with a combination of radiation and chemotherapy.
  • The pathology of the salivary gland tumors were mucoepidermoid carcinoma (10), adenoid cystic carcinoma (1) , and pleomorphic adenoma (1).
  • CONCLUSION: Radiation and chemotherapy used to treat patients with childhood malignancies increases the risk of developing a second neoplasm of salivary gland origin.
  • The majority of these neoplasms are malignant; mucoepidermoid carcinoma occurs most frequently.
  • The treatment of these tumors includes surgical excision of the primary, with neck dissection in patients with clinical evidence of nodal metastasis, and postoperative radiation added for pathologies with adverse features.
  • [MeSH-major] Neoplasms, Second Primary / diagnosis. Salivary Gland Neoplasms / diagnosis. Survivors
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


13. Védrine PO, Coffinet L, Temam S, Montagne K, Lapeyre M, Oberlin O, Orbach D, Simon C, Sommelet D: Mucoepidermoid carcinoma of salivary glands in the pediatric age group: 18 clinical cases, including 11 second malignant neoplasms. Head Neck; 2006 Sep;28(9):827-33
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of salivary glands in the pediatric age group: 18 clinical cases, including 11 second malignant neoplasms.
  • BACKGROUND: Salivary gland tumors represent 1% of head and neck tumors, with only 5% of these occurring in patients younger than 20 years.
  • Mucoepidermoid carcinoma (MEC) is one of the most frequent salivary gland cancers among adults and children.
  • RESULTS: Treatment included surgery or radiotherapy, or both.
  • Eleven patients had been previously treated by radiotherapy and/or chemotherapy for a first malignant tumor, specifically, lymphoid leukemia (n = 4), lymphoma (n = 3), brain tumor (n = 2), sarcoma (n = 1), and retinoblastoma (n = 1).
  • Treatment involves surgical removal of the tumor plus radiotherapy, according to histologic staging.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 16783829.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


1
Advertisement
4. Chandana SR, Conley BA: Salivary gland cancers: current treatments, molecular characteristics and new therapies. Expert Rev Anticancer Ther; 2008 Apr;8(4):645-52
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland cancers: current treatments, molecular characteristics and new therapies.
  • Salivary gland cancers are relatively rare and quite diverse.
  • Current therapy relies on local ablation.
  • There are few large clinical trials or randomized trials to guide treatment, especially for metastatic disease.
  • This article reviews the epidemiology, staging, molecular characteristics, and treatment evidence for the most common types of salivary cancers and suggests potential future diagnostic and treatment directions.
  • Progress in understanding the molecular and cell biology of salivary gland cancers may lead to the development of targeted therapies in these rare tumors.
  • Multidisciplinary and multi-institutional collaborative studies are needed to help improve survival in salivary gland cancers.
  • [MeSH-major] Adenocarcinoma. Salivary Gland Neoplasms
  • [MeSH-minor] Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / radiography. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / genetics. Carcinoma, Mucoepidermoid / radiography. Carcinoma, Mucoepidermoid / surgery. Humans. Mutation. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402531.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 81
  •  go-up   go-down


15. Laurie SA, Licitra L: Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol; 2006 Jun 10;24(17):2673-8
Hazardous Substances Data Bank. Trastuzumab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy in the palliative management of advanced salivary gland cancers.
  • Cancers of the salivary glands are unusual lesions that vary widely in their histologic appearance and molecular characteristics.
  • There are few data on the role of systemic therapies in the management of these cancers, and chemotherapy is generally reserved for the palliative management of advanced disease that is not amenable to local therapies such as surgery and/or radiation.
  • The majority of patients for whom systemic therapy is considered will have either adenoid cystic carcinoma, mucoepidermoid carcinoma, or high-grade adenocarcinoma.
  • This article will review the available literature regarding the use of palliative chemotherapy for patients with advanced salivary gland cancer of these histologies, with an emphasis on the potential role of targeted agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Mucoepidermoid / drug therapy. Neoplasm Recurrence, Local / drug therapy. Palliative Care. Salivary Ducts. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Boronic Acids / therapeutic use. Bortezomib. Clinical Trials as Topic. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Humans. Neoplasm Metastasis. Pyrazines / therapeutic use. Quinazolines / therapeutic use. Receptor, ErbB-2 / metabolism. Receptors, Androgen / metabolism. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763282.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 0 / Quinazolines; 0 / Receptors, Androgen; 0VUA21238F / lapatinib; 0W860991D6 / Deoxycytidine; 69G8BD63PP / Bortezomib; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Number-of-references] 87
  •  go-up   go-down


16. Taxy JB: Squamous carcinoma in a major salivary gland: a review of the diagnostic considerations. Arch Pathol Lab Med; 2001 Jun;125(6):740-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous carcinoma in a major salivary gland: a review of the diagnostic considerations.
  • CONTEXT: Squamous carcinoma in a major salivary gland has several possible sources:.
  • (1) high-grade mucoepidermoid carcinoma, (2) metastasis or direct invasion from a primary skin carcinoma, (3) metastasis from a distant primary carcinoma, or (4) a primary malignant neoplasm.
  • The latter is conventionally regarded as a diagnosis of exclusion after a history of squamous carcinoma elsewhere has been obtained or there is a positive mucin stain.
  • DESIGN: Eleven cases of squamous carcinoma in a major salivary gland are presented and the literature reviewed.
  • RESULTS: Two cases, 1 metastatic from a histologically identical squamous carcinoma from the ipsilateral tonsil and 1 with in situ squamous carcinoma in a duct, demonstrated positive mucicarmine stains.
  • Two cases were high-grade mucoepidermoid carcinomas, also with positive mucin stains.
  • CONCLUSION: The occurrence of squamous carcinoma in a major salivary gland exhibits a histologic sameness that precludes accurate subclassification and assignation of origin.
  • Also irrespective of tumor origin, the clinical approach to diagnosis and treatment is similar.
  • Adjuvant therapy (eg, radical neck dissection, radiation, chemotherapy) is not uniformly applied.
  • The traditional subclassification of squamous carcinoma in a major salivary gland may not be clinically relevant.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Mucins / metabolism. Parotid Neoplasms / metabolism. Parotid Neoplasms / pathology. Parotid Neoplasms / secondary. Submandibular Gland Neoplasms / metabolism. Submandibular Gland Neoplasms / pathology. Submandibular Gland Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371224.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 18
  •  go-up   go-down


17. Bell RB, Dierks EJ, Homer L, Potter BE: Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg; 2005 Jul;63(7):917-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and outcome of patients with malignant salivary gland tumors.
  • PURPOSE: Refined imaging technology, the use of external beam radiation, neutron beam therapy, and chemotherapy, has altered management strategies for patients with salivary gland malignancies during the past 2 decades.
  • Although treatment remains primarily surgical, optimal therapeutic regimens have yet to be fully realized.
  • The purpose of this investigation is to report our experience with the management of patients with a variety of malignant salivary gland neoplasms that were treated with various combinations of surgery, radiation, and chemotherapy and to review treatment outcome in an effort to identify predictors of survival and locoregional control.
  • MATERIALS AND METHODS: The records of all patients with malignant salivary gland tumors presenting for treatment at our institution between 1992 and 2002 were retrospectively reviewed.
  • The majority of tumors were located in the parotid gland (n = 42), with a significant minority located in the minor salivary glands (n = 29), followed by the submandibular gland (n = 8) and the sublingual gland (n = 6).
  • Mucoepidermoid carcinoma was the most common neoplasm (n = 40).
  • Neck dissection was performed in 29% of patients, and more than half (56%) were treated with adjuvant external beam radiation therapy to a dose of 50 to 70 Gy.
  • Patients were, in general, immediately reconstructed at the time of ablation using composite free tissue transfer when appropriate, local/regional rotational flaps, or maxillary obturators.
  • CONCLUSIONS: The treatment of salivary gland malignancies remains primarily surgical, although adjunctive radiotherapy may play an important role in those patients with advanced-stage disease.
  • The benefits of combined modality therapy awaits prospective clinical trials.
  • [MeSH-major] Carcinoma / therapy. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Invasiveness / prevention & control. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16003616.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Zeng Q, Tang PZ, Xu ZG, Qi YF, Wu XX, Liu WS: [Malignant minor salivary gland tumors of the larynx]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Jan;44(1):40-3
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant minor salivary gland tumors of the larynx].
  • OBJECTIVE: To study the clinical features, treatment and prognosis of malignant minor salivary gland tumors of the larynx.
  • METHODS: Treatment and outcome were retrospectively analyzed in a consecutive series of 15 patients with malignant minor salivary gland tumors of the larynx treated in this hospital from 1959 to 2005.
  • Ten patients (66.7%) had adenoid cystic carcinoma and 2 (13.3%) had adenocarcinoma.
  • The other three patients had mucoepidermoid carcinomas, polymorphic adenocarcinoma and base cell carcinoma respectively.
  • Fourteen had surgery (7 with adjuvant radiotherapy) and one was treated with radiotherapy plus chemotherapy.
  • The other 4 patients were lost to follow-up after treatment (ranging from 2 years to 16 years).
  • Seven patients developed recurrent disease, 1 of whom had local recurrence alone, 1 had regional recurrence alone, 2 had distant metastases alone, and 3 had local and distant metastases.
  • CONCLUSIONS: Minor salivary gland carcinomas of the larynx are rare and they are prone to the local recurrence and the distant metastasis in advanced stage.
  • Distant metastases remain the principal cause of treatment failure.
  • Surgery is the primary treatment modality used in most cases and the radiotherapy combining surgery has better local and regional control rate.
  • [MeSH-major] Laryngeal Neoplasms / therapy. Salivary Gland Neoplasms / therapy. Salivary Glands, Minor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484987.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Hatta C, Terada T, Okita J, Kakibuchi M, Kubota A, Sakagami M: Clinicopathological study of undifferentiated carcinoma of the parotid gland. Auris Nasus Larynx; 2003 Aug;30(3):273-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of undifferentiated carcinoma of the parotid gland.
  • OBJECTIVE: Undifferentiated carcinoma of the salivary gland is a rare malignant tumor, and is difficult to distinguish from other poorly differentiated types of carcinoma or sarcoma.
  • The present study investigated clinical and pathological characteristics for undifferentiated carcinoma of the parotid gland.
  • PATIENTS AND METHODS: Forty-four patients with previously untreated carcinoma of the major salivary glands were treated at our institution between 1986 and 1999.
  • Of these, five patients (two males, three females) were diagnosed with undifferentiated carcinoma of the parotid gland and treated.
  • Tumors in these two patients included a small portion of poorly differentiated epidermoid or mucoepidermoid carcinoma.
  • The remaining three patients did not show any differentiated portions, and histological findings demonstrated heterogeneous patterns of lymphoepithelial carcinoma, small cell carcinoma and unclassified (a pattern of malignant hemangiopericytoma), respectively.
  • CONCLUSIONS: Investigation using multislice sections is needed to diagnose undifferentiated carcinoma of the salivary glands.
  • Regarding prognosis, carcinoma that is too poorly differentiated but including slightly-differentiated portions should be considered undifferentiated carcinoma.
  • All patients died of distant metastasis despite radical surgery, suggesting that chemotherapy is needed to improve patient outcomes.
  • [MeSH-major] Carcinoma / pathology. Parotid Gland / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12927291.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, Forastiere AA: Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck; 2006 Mar;28(3):197-204
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
  • BACKGROUND: Malignant tumors of the salivary glands make up approximately 5% of head and neck cancers.
  • The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies.
  • METHODS: Chemo-naive patients with histologically confirmed recurrent or metastatic carcinoma of salivary gland origin (mucoepidermoid, adenocarcinoma, or adenoid cystic) were eligible.
  • Eight partial responses were seen among the 31 patients with mucoepidermoid or adenocarcinoma histologic findings for a response rate of 26%.
  • No responses were seen in the adenoid cystic carcinoma group.
  • CONCLUSION: Paclitaxel demonstrates moderate activity in salivary gland tumors of mucoepidermoid and adenocarcinoma histology.
  • The poor response rate in adenoid cystic carcinoma is consistent with prior reports in this chemoresistant histologic subtype.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / mortality. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 16470745.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14548; United States / NCI NIH HHS / CA / CA16116; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S, Bumma C: Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer; 2001 Feb 1;91(3):541-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.
  • BACKGROUND: Some previous studies have shown that vinorelbine (VNB) is active in recurrent salivary gland tumors.
  • Four patients had been treated with prior surgery (S) or radiotherapy (RT), 27 patients had been treated with S plus RT, and 5 patients had been treated with S plus RT plus mitoxantrone.
  • Eighteen patients had major salivary gland tumors, and 18 patients had minor salivary gland tumors; 9 patients had adenocarcinoma, 22 patients had adenoid cystic carcinoma, 1 patient had a malignant mixed carcinoma, 3 patients had undifferentiated carcinoma, and 1 patient had a mucoepidermoid carcinoma.
  • Grade 2-3 nausea and emesis was statistically higher (P < 0.001) in Arm A; there was no significant difference with regard to other side-effects between the two treatment arms.
  • CONCLUSIONS: VNB is a drug with moderate activity in salivary gland malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Salivary Gland Neoplasms / drug therapy. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11169936.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


22. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol; 2003 Oct;39(7):724-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.
  • Phase II study of Herceptin (Trastuzumab) in patients with advanced salivary gland tumors overexpressing Her2/neu.
  • Patients with advanced, incurable salivary gland tumors and 2(+) or 3(+) Her2/neu expression in their tumors were enrolled in the study.
  • Median time to progression was 4.2 months.
  • One patient with metastatic mucoepidermoid carcinoma has received 40 cycles of Herceptin to date with a documented partial response.
  • Herceptin given as a single agent has a low activity in salivary gland tumors overexpressing Her2/neu.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oral Oncol. 2005 Jan;41(1):97-8 [15598592.001]
  • (PMID = 12907212.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


23. Cheuk DK, Shek TW, Chan GC, Lau YL, Ha SY, Chiang AK: Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Mar;50(3):636-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
  • Salivary gland tumors account for about 6% of the second cancers.
  • The majority of these are mucoepidermoid carcinomas (MEC) of the parotid gland.
  • We report the clinical and pathological features of a rarer histological type, acinic cell carcinoma (ACC), in a childhood acute lymphoblastic leukemia (ALL) survivor.
  • The behavior of secondary ACC appears similar to primary tumor and similar treatment may be adopted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Acinar Cell / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Whole-Body Irradiation / adverse effects
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. 6-Mercaptopurine / adverse effects. Adenoma, Sweat Gland / etiology. Adenoma, Sweat Gland / surgery. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child, Preschool. Combined Modality Therapy / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Prednisolone / administration & dosage. Prednisolone / adverse effects. Recurrence. Remission Induction. Survivors. Sweat Gland Neoplasms / etiology. Sweat Gland Neoplasms / surgery. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16865683.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; UKALL X protocol
  • [Number-of-references] 17
  •  go-up   go-down


24. Yoo GH, Subramanian G, Piechocki MP, Ensley JF, Kucuk O, Tulunay OE, Lonardo F, Kim H, Won J, Stevens T, Lin HS: Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models. Arch Otolaryngol Head Neck Surg; 2008 Jul;134(7):735-42
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To identify the antitumor activity and wound-healing effect of docetaxel delivered in the surgical tumor microenvironment of head and neck squamous cell carcinoma (HNSCC).
  • INTERVENTION: Intrawound (IW) docetaxel therapy was tested in 3 HNSCC xenograft and 2 taxane-resistant models.
  • Intratumoral (IT) docetaxel therapy was further tested in the 2 taxane-resistant models.
  • RESULTS: In a pilot study using BALB/c mice, IW docetaxel therapy was not associated with problems in wound healing.
  • Using taxane-resistant xenograft lung cancer (H460/T800) and syngeneic salivary cancer (BALB/c mucoepidermoid carcinoma) models, IW therapy did not delay tumor growth.
  • An antitumor effect was detected with repeated docetaxel injections in the H460/T800 taxane-resistant model but not in the BALB/c mucoepidermoid carcinoma model.
  • CONCLUSIONS: These preclinical results support further testing of IW docetaxel treatment in HNSCC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / pathology. Disease Models, Animal. Otorhinolaryngologic Neoplasms / pathology. Taxoids / pharmacology. Wound Healing / drug effects
  • [MeSH-minor] Animals. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Drug Resistance, Neoplasm. Injections, Intralesional. Lung Neoplasms / pathology. Mice. Mice, Inbred BALB C. Mice, SCID. Neoplasm Transplantation. Pilot Projects. Salivary Gland Neoplasms / pathology. Tumor Burden

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645124.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


25. Chang SM, Xing RD, Zhang FM, Duan YQ: Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy. Oral Dis; 2009 Nov;15(8):570-2
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the levels of serum sCD44v6 in patients with oral cancer and evaluate the value of serum sCD44v6 in adjuvant diagnosis, staging and monitoring treatment response in these patients.
  • One week after treatment, venous blood was collected once again in 60 patients with oral and maxillofacial squamous cell carcinoma (OSCC).
  • The levels of serum sCD44v6 in patients with OSCC and salivary carcinoma showed no difference with those in control group (P > 0.05).
  • Serum sCD44v6 levels in patients with OSCC after treatment became lower than that prevailed during pretreatment (P < 0.05).
  • CONCLUSION: The possible roles of CD44v6 in the diagnosis of oral and maxillofacial malignancy deserve further elucidation and evaluation.
  • Serum sCD44v6 may be a valuable marker in monitoring treatment response in patients with OSCC.
  • [MeSH-major] Antigens, CD44 / blood. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / blood. Head and Neck Neoplasms / blood. Mouth Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / blood. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / blood. Carcinoma, Mucoepidermoid / drug therapy. Carcinoma, Mucoepidermoid / surgery. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Reference Values. Salivary Gland Neoplasms / blood. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563418.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen
  •  go-up   go-down


26. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • There were 25 squamous cell carcinomas, 14 undifferentiated carcinomas, 31 minor salivary gland tumors (adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma), 8 esthesioneuroblastomas, and 1 transitional cell carcinoma.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement